In today’s briefing:
- Onewo Space-Tech Pre-IPO – PHIP Updates – Topline Still Strong YoY, Sequentially Cracks Emerging
- Kintor Pharmaceutical (9939.HK) Placement – The Hidden Risks and the True Colors
Onewo Space-Tech Pre-IPO – PHIP Updates – Topline Still Strong YoY, Sequentially Cracks Emerging
- Onewo Space-Tech (OST) aims to raise upto US$2bn in its Hong Kong IPO. OST is a property management service provider primarily owned by China Vanke Co Ltd (H) (2202 HK).
- As per Frost & Sullivan, amongst the residential community service providers in China, OST ranked first. It also ranked first in the commercial space integrated services market in China.
- In this note, we talk about the updates from its recently filed PHIP.
Kintor Pharmaceutical (9939.HK) Placement – The Hidden Risks and the True Colors
- Over the past year, we’ve seen the stock price of Kintor fluctuate largely, which was mainly driven by its COVID-19 drug proxalutamide. However, we are not optimistic about its outlook.
- There are big concerns about the credibility of management. The suspicion caused by mistrust leads us to suggest that investors directly enter the “show me the result” mode.
- Shares plunged after the announcement of the Placing. Obviously, Kintor Pharmaceutical (9939 HK) is short of money. Considering the potential risks behind, we are bearish on Kintor.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
